Answers are grounded in this paper and cite their sources.
The insulin-like growth factor-I receptor (IGF-1R) and its ligands (IGF-I, IGF-II) have been shown to be important promoters of cancer development and are frequently overexpressed in most hepatocellular carcinomas (HCCs). The activation of IGF-1R signaling mediates tumorigenesis, proliferation, and metastasis and thus represents a potential target for innovative treatment strategies for HCC. We investigated the potential inhibitory effect and mechanism of the impact of a novel IGF-1R inhibitor, picropodophyllin (PPP), in HCC lines. It was found that PPP selectively induced cell apoptosis in a time- and dose-dependent manner in HCC cells compared to normal hepatocytes. The inhibitory effects had a positive correlation with the expression of IGF-1R. PPP exerted an apoptotic effect in HCC cells in a caspase-dependent manner through the mitochondrial pathway. The release of cytochrome C from the mitochondrion was coupled with activation of caspase-9 and caspase-3. Treatment of PPP in HepG2 cells resulted in a marked elevation of Bax protein, but decreased levels of phosphorylated Akt and Bcl-2 protein. The ratio of Bax/Bcl-2 was increased in a dose-dependent manner. Our study provides strong evidence that the IGF-1R inhibitor PPP selectively inhibits the growth of human hepatocellular cancer cells by inducing the caspase-dependent mitochondrial pathway cell apoptosis pathway with no observed cytotoxicity on normal cells.
No takes yet. Share an insight, caveat, or question.
Changyong et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: